Johnson & Johnson submits applications for new indications for Darzalex
The Fly

Johnson & Johnson submits applications for new indications for Darzalex

Johnson & Johnson announced the submission of regulatory applications to the U.S. FDA and European Medicines Agency seeking approval of a new indication for Darzalex Faspro in the U.S. and Darzalex subcutaneous formulation in the European Union. The applications are supported by data from the ongoing Phase 3 AQUILA study of Darzalex Faspro as monotherapy for the treatment of adult patients with high-risk smoldering multiple myeloma.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App